Logo

Epigenomics, Myriad to Hunt DNA Methylation Markers for Cancer Drug Response

May 09, 2007
NEW YORK (GenomeWeb News) - Epigenomics today said it will collaborate with Myriad Genetics to identify DNA methylation biomarkers that may predict patient response to a cancer drug.
 
Under the collaboration, Epigenomics will use its Differential Methylation Hybridization microarray platform for genome-wide profiling of samples provided by Myriad. The company hopes to discover methylation biomarkers that are linked to sensitivity and resistance to the undisclosed marketed oncology drug.
 
Epigenomics also said it will use its proprietary OncoSign identification approach through a collaboration with its partner CellTrend for rapid identification of biomarkers in a panel of human tumor cell lines.
 
Financial terms of the agreement were not released.

Filed under

Microarrays & Multiplexing
microarrays
Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.